Le Lézard
Classified in: Health, Business
Subjects: CON, LIC, PET, ANW

MicroSintesis and Bio Agri Mix Sign Exclusive Agreement to Market Game-Changing Proteobiotic Technology to Canadian Swine Producers



Distribution agreement will create opportunities to reduce antibiotic use in the future

MITCHELL, ON, Oct. 5, 2017 /CNW/ - MicroSintesis and Bio Agri Mix have signed a distribution agreement to market a unique Proteobiotic technology for Canadian swine production.

Nuvio is the first product made of protein sources that contain probiotic molecules, termed Proteobiotics, which have been proven in clinical trials to significantly improve producer outcomes when faced with post-weaning diarrhea challenges.

Bacteria use a mechanism called Quorum Sensing that lets them communicate with each other and act as a unified group. This communication process enables bacteria to express virulence factors such as biofilm formation, adhesion, invasion and toxin release. Proteobiotics use a non-antibiotic, anti-infective mode of action that supports the gut's natural immune defences by stopping the cell-to-cell communication of these bacteria. In recent trials, the product was 86% effective at reducing clinical diarrhea symptoms with statistically significant improvements in weight gain and feed conversion during the trial period.

Initially discovered at the University of Guelph, the development of the product has been a collaborative effort between MicroSintesis and the University of Guelph, and has been independently validated in clinical research studies as well as in a veterinary monitored commercial field trial. 

"Nuvio has the potential to be a new, first-line product in the fight against the production problems associated with post-weaning diarrhea," said Trevor Lank, Swine Technical Consultant for MicroSintesis. "It can be easily administered with other products such as vaccines or antibiotics without withdrawal periods, and because the proteobiotics work on reducing bacteria communication, no period for immunity building is required. The proteobiotics simultaneously reduce the pathogenic bacteria's effectiveness while increasing the ratio of the natural gut flora. It is truly an all-in-one technology."

Dr. Robert Bell, CEO of Bio Agri Mix, added, "Over my forty-year career in the animal health industry, I have witnessed the launch of a handful of revolutionary technologies; endectocides, prostaglandins and long-lasting time dependent antimicrobials, and there is no doubt Nuvio is in the same league with these game-changing products, particularly when the animal health industry is tasked with ensuring prudent antimicrobial use and reduced antimicrobial resistance.  Nuvio has been proven to be clinically effective in conventional swine systems and will fill a unique void for "raised without antimicrobial" swine production."

"MicroSintesis is delighted to have partnered with Bio Agri Mix on the commercialization of this technology. Bio Agri Mix has a proven track record not only in marketing water solubles, but has a strong commitment to leading the way through the changing antimicrobial-use regulations," said Hannah McIver, CEO of MicroSintesis.

Nuvio is administered in the drinking water for the first 14 days post-weaning. It will be available through veterinarians and feed companies beginning October 2017. 

About MicroSintesis
Founded in 2011, MicroSintesis is a Canadian life sciences company focused on creating novel anti-infectives. By harnessing the natural defense mechanisms of probiotics, MicroSintesis is on the forefront of new bio-technologies that fight antibiotic resistant bacteria and reduce the virulence of pathogens: an animal health company pioneering gut health through proteobiotics.

MicroSintesis has developed a unique technology to reduce antibiotic use and create a first line of defense in the fight against antibiotic resistance bacteria. MicroSintesis manufactures to the highest standard of quality assurance, resulting in products that are simple, natural, well-defined, and supported by clinical assays, for deliverable success.

About Bio Agri Mix
Proudly Canadian owned and operated, Bio Agri Mix LP is Canada's largest manufacturer and distributor of medicated feed additives and water soluble medications. For more than 30 years, the company has supplied feedmills and producers with the quality products they need to improve animal health. Today Bio Agri Mix offers the largest range of products in the industry, including: Feed Medications; Disinfectants; Water Solubles; Feed Enzymes; and Anthelmintics & Parasiticides.

The company's signature granulation technique allows feedmills and producers to more accurately dose livestock. Bio Agri Mix is Health Canada, FDA, ISO 9001 and HACCP certified.

SOURCE MicroSintesis


These press releases may also interest you

at 01:30
CTI BioPharma Corp. today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of...

17 jan 2018
Fluke Biomedical, RaySafe and LANDAUER will be demonstrating several new products at the Arab Health Exhibition and Congress held 29 January through 1 February at the Dubai International Convention and Exhibition Centre, Dubai, United Arab Emirates....

17 jan 2018
Today, the U.S. Patent & Trademark Office (PTO) issued a final written decision in Argentum Pharmaceuticals LLC's inter partes review (IPR) against the sole unexpired patent listed as covering Janssen Oncology, Inc.'s ZYTIGA® (abiraterone acetate)...

17 jan 2018
WELL is pleased to announce the launch of its WELL Web Platform for both patients and providers, delivering convenient healthcare anytime, anywhere. WELL's simple, easy to navigate telemedicine platform connects patients worldwide to a global...

17 jan 2018
Safa M. Osman, MD is recognized by Continental Who's Who as a Pinnacle Professional Member in the field of Internal Medicine in recognition of her role as an Internist at Valley Health Internal Medicine.                 Dedicated to the health and...

17 jan 2018
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 clinical trial for GC1102 (also known as Hepabig-gene), the company's investigational...




News published on 5 october 2017 at 11:10 and distributed by: